Expert Review of Clinical Immunology最新文献_第6页

Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling. 特应性皮炎分层：皮肤和血液转录组学与蛋白质组学分析的现状与未来展望。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-03-04 DOI: 10.1080/1744666X.2024.2323964

Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger

{"title":"Atopic dermatitis stratification: current and future perspective on skin and blood transcriptomic and proteomic profiling.","authors":"Kelly Hawkins, Eden David, Jacob W Glickman, Ester Del Duca, Emma Guttman-Yassky, James G Krueger","doi":"10.1080/1744666X.2024.2323964","DOIUrl":"10.1080/1744666X.2024.2323964","url":null,"abstract":"Introduction: Atopic dermatitis (AD) is a common, chronic inflammatory skin disorder driven by an intricate interplay of genetic, environmental, and immunological factors.Areas covered: As a clinically heterogenous condition, AD may be stratified into subtypes based on factors including, chronicity, immunoglobulin E levels, severity, age, and ethnicity. Transcriptomic and proteomic analyses in skin and blood help elucidate the underlying molecular mechanisms of these AD subtypes, referred to as AD endotypes. Further characterizing AD endotypes using reliable biomarkers can facilitate the development of more effective and personalized therapeutics and improve our tools for monitoring disease progression and therapeutic response across a diverse subset of patients. Here, we aim to provide perspective on the latest research regarding AD stratification using skin and blood-based studies and insight into the implications of these findings on the future of AD research and clinical practice.Expert opinion: The precise stratification of AD endotypes will allow for the development of reliable biomarkers and a more personalized medical treatment approach. Clinical practice and trials will eventually be able to bridge clinical with molecular data to optimize individualized treatments and more effectively monitor treatment response.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1083-1088"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140021288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immunology and targeted therapy in Castleman disease. 卡斯特曼病的免疫学和靶向治疗。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-27 DOI: 10.1080/1744666X.2024.2357689

Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki

{"title":"Immunology and targeted therapy in Castleman disease.","authors":"Shinichiro Tsunoda, Takuya Harada, Yoshikane Kikushige, Tadamitsu Kishimoto, Kazuyuki Yoshizaki","doi":"10.1080/1744666X.2024.2357689","DOIUrl":"10.1080/1744666X.2024.2357689","url":null,"abstract":"Introduction: Castleman disease (CD) is a benign lymphoproliferative disease causing severe systemic inflammation. Interleukin-6 (IL-6) is a major pathogenesis of multicentric CD (MCD), but only 30-60% of patients respond to IL-6 inhibitors. Novel agents for IL-6 inhibitor-refractory cases are needed. Clinical data and samples are being collected on a large scale and the clinical, pathological, and pathogenetic aspects are being elucidated.Areas covered: The pathological and clinical classification of CD is outlined. Focusing on idiopathic MCD (iMCD), this review identifies therapeutic targets and summarizes currently recommended drugs and promising therapeutic candidates.Expert opinion: The pathogenesis of MCD has been implicated in the activation of the Janus kinase (JAK)-transcriptional signaling activator (STAT) 3 pathway and the phosphatidylinositol 3-kinase (PI3K)/Akt/mechanical target of rapamycin (mTOR) signaling pathway. iMCD-TAFRO (thrombocytopenia, anasarca, fever/elevated CRP, reticulin myelofibrosis/renal dysfunction, organ enlargement) is resistant to IL-6 inhibitors, and cyclosporine and mTOR inhibitors are sometimes effective. JAK inhibitors and mTOR inhibitors may be therapeutic agents for iMCD. Recently, we have shown that peripheral helper T (Tph) cell abnormalities are at the core of iMCD pathogenesis. Therapies targeting chemokine (C-X-C motif) ligand 13 (CXCL13) produced by Tph cells and blocking the Tph-CXCL13-B cell pathway may satisfy unmet need in refractory cases.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1101-1112"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141087405","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease. 拓宽巨细胞动脉炎的临床范围：从典型的颅内疾病到以颅外为主的疾病模式。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-21 DOI: 10.1080/1744666X.2024.2356741

Miguel Ángel González-Gay, Elena Heras-Recuero, Teresa Blázquez-Sánchez, Claritza Caraballo-Salazar, Fernando Rengifo-García, Santos Castañeda, Raquel Largo

{"title":"Broadening the clinical spectrum of giant cell arteritis: from the classic cranial to the predominantly extracranial pattern of the disease.","authors":"Miguel Ángel González-Gay, Elena Heras-Recuero, Teresa Blázquez-Sánchez, Claritza Caraballo-Salazar, Fernando Rengifo-García, Santos Castañeda, Raquel Largo","doi":"10.1080/1744666X.2024.2356741","DOIUrl":"10.1080/1744666X.2024.2356741","url":null,"abstract":"Introduction: Giant cell arteritis (GCA) is a large vessel (LV) vasculitis that affects people aged 50 years and older. Classically, GCA was considered a disease that involved branches of the carotid artery. However, the advent of new imaging techniques has allowed us to reconsider the clinical spectrum of this vasculitis.Areascovered: This review describes clinical differences between patients with the cranial GCA and those with a predominantly extracranial LV-GCA disease pattern. It highlights differences in the frequency of positive temporal artery biopsy depending on the predominant disease pattern and emphasizes the relevance of imaging techniques to identify patients with LV-GCA without cranial ischemic manifestations. The review shows that so far there are no well-established differences in genetic predisposition to GCA regardless of the predominant phenotype.Expert commentary: The large branches of the extracranial arteries are frequently affected in GCA. Imaging techniques are useful to identify the presence of 'silent' GCA in people presenting with polymyalgia rheumatica or with nonspecific manifestations. Whether these two different clinical presentations of GCA constitute a continuum in the clinical spectrum of the disease or whether they may be related but are definitely different conditions needs to be further investigated.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1089-1100"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140956958","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Navigating the crossroads: asthma, trained immunity, and infection susceptibility. 十字路口的导航：哮喘、训练有素的免疫力和感染易感性。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-09 DOI: 10.1080/1744666X.2024.2353743

Ahmad Z Al Meslamani, Eman Merghani Ali

引用次数: 0

Lymphocyte-C-reactive protein ratio combined with albumin upon admission predicts coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease: a retrospective cohort study. 淋巴细胞-C反应蛋白比值与白蛋白结合可预测川崎病儿科患者的冠状动脉扩张和动脉瘤形成：一项回顾性队列研究。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-07-31 DOI: 10.1080/1744666X.2024.2385765

Yajun Wang, Yilu Lin, Lei Zhang, Di Wu, Yujia Tang, Huan Meng, Huiying Liu, Xiaohui Jiang, Guoli Zhang, Yang Yang, Fengmei Li, Yajun Shu, Kai Kang, Ligang Si, Yang Gao

{"title":"Lymphocyte-C-reactive protein ratio combined with albumin upon admission predicts coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease: a retrospective cohort study.","authors":"Yajun Wang, Yilu Lin, Lei Zhang, Di Wu, Yujia Tang, Huan Meng, Huiying Liu, Xiaohui Jiang, Guoli Zhang, Yang Yang, Fengmei Li, Yajun Shu, Kai Kang, Ligang Si, Yang Gao","doi":"10.1080/1744666X.2024.2385765","DOIUrl":"10.1080/1744666X.2024.2385765","url":null,"abstract":"Background: We aimed to explore simple and effective clinical parameters or combinations to predict coronary artery dilation and aneurysm formation in pediatric patients with Kawasaki disease (KD).Design and methods: This retrospective cohort study included pediatric patients with KD from January, 2013 to December, 2022. Multiple demographic and clinical data were collected, collated, and calculated from the medical records. Then they were divided into the coronary artery dilation and aneurysm formation group or the non-coronary artery dilation and aneurysm formation group. Lymphocyte-C-reactive protein ratio (LCR) was transformed into its natural logarithm and expressed as lnLCR.Results: A total of 64 pediatric patients with KD were enrolled in this cohort study after 1:3 propensity score matching (PSM). For each unit increase in lnLCR, the possibility of coronary artery dilation and aneurysm formation decreased to 0.419 times the original value. The areas under the receiver operating characteristic (ROC) curves of lnLCR combined with albumin (ALB), ALB, and lnLCR to classify pediatric patients with KD into the coronary artery dilation and aneurysm formation group were 0.781, 0.692, and 0.743, respectively.Conclusion: LCR combined with ALB upon admission is a promising predictor of coronary artery dilation and aneurysm formation in pediatric patients with KD.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1127-1133"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141787667","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity. CSE1L 是与泛癌免疫浸润和药物敏感性相关的预后生物标志物。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-05-23 DOI: 10.1080/1744666X.2024.2356747

Haiyang Li, Lingwa Wang, Zhaohui Ruan, Xiaoyan Li, Yifan Yang, Jugao Fang, Ru Wang

{"title":"CSE1L as a prognostic biomarker associated with pan cancer immune infiltration and drug sensitivity.","authors":"Haiyang Li, Lingwa Wang, Zhaohui Ruan, Xiaoyan Li, Yifan Yang, Jugao Fang, Ru Wang","doi":"10.1080/1744666X.2024.2356747","DOIUrl":"10.1080/1744666X.2024.2356747","url":null,"abstract":"Background: Rising cancer-related mortality underscores the importance of biomarkers for treatment and prognosis, with Chromosome Segregation 1 Like (CSE1L) linked to various cancers yet its roles remain partially understood. This study investigates CSE1L's expression and oncogenic mechanisms in solid tumors.Research design and methods: We analyzed multi-omics data from 31 solid tumors, measured CSE1L in 41 head and neck carcinoma patients post-chemotherapy via qRT-PCR, and evaluated the impact of CSE1L knockdown on cell proliferation in A549 and HepG2 cells.Results: In this study, we observed significantly elevated levels of CSE1L RNA in 13 tumor tissues and protein levels in 8 tumor tissues compared to their corresponding adjacent normal tissues. Additionally, our investigation unveiled a correlation between heightened CSE1L expression in tumor tissues and worsened patient prognosis, poor response to immunotherapy, and diminished effectiveness of neoadjuvant chemotherapy. Through an analysis of CSE1L mechanisms, we discovered its potential involvement in promoting tumor cell proliferation, enhancing drug resistance, and influencing immune infiltration, thereby impacting patient prognosis and treatment outcomes. Finally, we delved into the potential mechanisms underlying upregulation of CSE1L in tumor tissues.Conclusion: Our findings demonstrate that CSE1L promotes tumor development in various malignancies, highlighting its potential as both a therapeutic target and prognostic indicator.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1113-1125"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140944449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

How could our genetics impact COVID-19 vaccine response? 我们的基因如何影响 COVID-19 疫苗的反应？

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-09-01 Epub Date: 2024-04-27 DOI: 10.1080/1744666X.2024.2346584

Keyi Zheng, Amanda Y Chong, Alexander J Mentzer

{"title":"How could our genetics impact COVID-19 vaccine response?","authors":"Keyi Zheng, Amanda Y Chong, Alexander J Mentzer","doi":"10.1080/1744666X.2024.2346584","DOIUrl":"10.1080/1744666X.2024.2346584","url":null,"abstract":"Introduction: The COVID-19 pandemic, caused by the SARS-CoV-2 virus, has posed unprecedented global health challenges since its emergence in December 2019. The rapid availability of vaccines has been estimated to save millions of lives, but there is variation in how individuals respond to vaccines, influencing their effectiveness at an individual, and population level.Areas covered: This review focuses on human genetic factors influencing the immune response and effectiveness of vaccines, highlighting the importance of associations across the HLA locus. Genome-Wide Association Studies (GWAS) and other genetic association analyses have identified statistically significant associations between specific HLA alleles including HLA-DRB1*13, DBQ1*06, and A*03 impacting antibody responses and the risk of breakthrough infections post-vaccination. Relationships between these associations and potential mechanisms and links with risks of natural infection or disease are explored, and this review concludes by emphasizing how understanding the mechanisms of these genetic determinants may inform the development of tailored vaccination strategies.Expert opinion: Although complex, we believe these findings from the SARS-CoV2 pandemic offer a unique opportunity to understand the relationships between HLA and infection and vaccine response, with a goal of optimizing individual protection against COVID-19 in the ongoing pandemic, and possibly influencing wider vaccine development in the future.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1027-1039"},"PeriodicalIF":3.9,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140853090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Endosomal Toll-Like Receptors intermediate negative impacts of viral diseases, autoimmune diseases, and inflammatory immune responses on the cardiovascular system. 内体 Toll-Like 受体是病毒性疾病、自身免疫性疾病和炎症性免疫反应对心血管系统产生负面影响的中间环节。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-20 DOI: 10.1080/1744666X.2024.2392815

Fatemeh Sadat Tabatabaei, Melika Shafeghat, Amirali Azimi, Ashley Akrami, Nima Rezaei

{"title":"Endosomal Toll-Like Receptors intermediate negative impacts of viral diseases, autoimmune diseases, and inflammatory immune responses on the cardiovascular system.","authors":"Fatemeh Sadat Tabatabaei, Melika Shafeghat, Amirali Azimi, Ashley Akrami, Nima Rezaei","doi":"10.1080/1744666X.2024.2392815","DOIUrl":"10.1080/1744666X.2024.2392815","url":null,"abstract":"Introduction: Cardiovascular disease (CVD) is the leading cause of morbidity globally, with chronic inflammation as a key modifiable risk factor. Toll-like receptors (TLRs), pivotal components of the innate immune system, including TLR-3, -7, -8, and -9 within endosomes, trigger intracellular cascades, leading to inflammatory cytokine production by various cell types, contributing to systemic inflammation and atherosclerosis. Recent research highlights the role of endosomal TLRs in recognizing self-derived nucleic acids during sterile inflammation, implicated in autoimmune conditions like myocarditis.Areas covered: This review explores the impact of endosomal TLRs on viral infections, autoimmunity, and inflammatory responses, shedding light on their intricate involvement in cardiovascular health and disease by examining literature on TLR-mediated mechanisms and their roles in CVD pathophysiology.Expert opinion: Removal of endosomal TLRs mitigates myocardial damage and immune reactions, applicable in myocardial injury. Targeting TLRs with agonists enhances innate immunity against fatal viruses, lowering viral loads and mortality. Prophylactic TLR agonist administration upregulates TLRs, protecting against fatal viruses and improving survival. TLRs play a complex role in CVDs like atherosclerosis and myocarditis, with therapeutic potential in modulating TLR reactions for cardiovascular health.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"1-13"},"PeriodicalIF":3.9,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141975450","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions. 晚期食管鳞状细胞癌免疫疗法的进展：当前策略与未来方向的全面回顾。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-06-17 DOI: 10.1080/1744666X.2024.2368194

Yi Zhang, Zheng Li, Ying Huang, Yong Xu, Bingwen Zou

{"title":"Advancements in immunotherapy for advanced esophageal squamous cell carcinoma: a comprehensive review of current strategies and future directions.","authors":"Yi Zhang, Zheng Li, Ying Huang, Yong Xu, Bingwen Zou","doi":"10.1080/1744666X.2024.2368194","DOIUrl":"10.1080/1744666X.2024.2368194","url":null,"abstract":"Introduction: Esophageal cancer (EC), particularly esophageal squamous cell carcinoma (ESCC), is characterized by high incidence and poor prognosis worldwide, necessitating novel therapeutic approaches like immunotherapy. This review explores the impact of immune checkpoint inhibitors (ICIs) on ESCC, especially focusing on PD-1/PD-L1 and CTLA-4 inhibitors. Our literature search, conducted across databases including PubMed, Web of Science, and EMBASE, from January 2010 to December 2023, aimed at identifying advancements, challenges, and future directions in the use of immunotherapy for ESCC.Areas covered: We provide a detailed analysis of clinical trials evaluating the efficacy of ICIs as monotherapy and in combination with chemotherapy, radiotherapy, and targeted therapy for locally advanced ESCC. Our findings highlight the significant survival benefits offered by ICIs, albeit with varying efficacy across patient populations, emphasizing the need for precise biomarkers to tailor treatment strategies.Expert opinion: The integration of immunotherapy into the ESCC treatment paradigm represents a significant shift, improving survival outcomes. Future research should focus on optimizing combination therapies and novel immunotherapeutic agents, incorporating genetic and tumor microenvironment analyses to enhance patient selection and treatment efficacy.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"971-984"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141330696","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy. 癌症免疫疗法中免疫检查点抑制剂的风湿不良反应。

IF 3.9 3区医学

Expert Review of Clinical Immunology Pub Date : 2024-08-01 Epub Date: 2024-03-19 DOI: 10.1080/1744666X.2024.2323966

Noha Abdel-Wahab, Maria E Suarez-Almazor

{"title":"Rheumatic adverse events of immune checkpoint inhibitors in cancer immunotherapy.","authors":"Noha Abdel-Wahab, Maria E Suarez-Almazor","doi":"10.1080/1744666X.2024.2323966","DOIUrl":"10.1080/1744666X.2024.2323966","url":null,"abstract":"Introduction: The advent of immune checkpoint inhibitors (ICIs) in cancer treatment has marked a transformative era, albeit tempered by immune-related adverse events (irAEs), including those impacting the musculoskeletal system. The lack of precise epidemiologic data on rheumatic irAEs is attributed to factors such as potential underrecognition, underreporting in clinical trials, and the tendency to overlook manifestations without immediate life-threatening implications, further complicating the determination of accurate incidence rates, while the complete understanding of the mechanisms driving rheumatic irAEs remains elusive.Areas covered: This literature review comprehensively examines rheumatic irAEs in cancer patients undergoing ICI therapy, encompassing epidemiology, risk factors, mechanisms, clinical manifestations, and current management guidance for prevalent conditions such as inflammatory arthritis, polymyalgia rheumatica, and myositis. Less frequent rheumatic and musculoskeletal irAEs are also explored, alongside insights into ongoing clinical trials testing therapeutic and preventive strategies for irAEs. A thorough literature search on Medline and the National Cancer Institute Clinical Trials Database was conducted up to October 2023 to compile relevant information.Expert opinion: In light of the evolving landscape of cancer immunotherapy, there is a compelling need for prospective longitudinal studies to enhance understanding and inform clinical management strategies for rheumatic irAEs.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"873-893"},"PeriodicalIF":3.9,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11449381/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139944061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0